AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06309459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carbonic anhydrase staining levels
Description: CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
Study NCT02085603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib
Study NCT02085603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01736579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Study NCT01826552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osiro Hybrid Drug-Eluting Stent
Description: Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
Study NCT01826552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity
Description: Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
Study NCT01908101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT01908101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03797625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60mg/m2，D1，8
Study NCT03797625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: 60mg/m2，D1
Study NCT03797625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 15mg/d，d1-d7 civ
Study NCT01394939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Study NCT01394939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV every 2 weeks.
Study NCT00107237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Description: AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
Study NCT00107237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
Study NCT00193765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective neck dissection in early oral cancer
Description: Elective neck dissection in early node negative oral cancers at the time of primary surgery
Study NCT00193765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Neck Dissection
Description: There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
Study NCT01573715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIMBEX
Study NCT01573715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMBEX
Study NCT01573715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WITHOUT NIMBEX
Study NCT01573715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WITHOUT NIMBEX
Study NCT00959816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Toddler Drink
Description: 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Toddler Drink
Description: 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supplemental Formula for HM Group
Description: Ad libitum formula given up to 12 months of age if HM is supplemented
Study NCT04495738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Toddler Drink for HM group
Description: 16 fl oz per day if weaned from HM feedings
Study NCT03278132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
Study NCT04509310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Bodysuits
Description: The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
Study NCT00294307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Augmented Standard Care (ASC)
Description: Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];
Study NCT00294307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Resource Nurse Care (RNC)
Description: Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.
Study NCT00294307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Advanced Practice Nurse Care (APNC)
Description: Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
Study NCT03741998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal airway
Description: THRIVE with a regular nasopharyngeal airway.
Study NCT02542475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
Study NCT03090126 — intervention group
Intervention type: OTHER
Intervention: Therapeutic education
Description: Questionnaires
Study NCT03691974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Subcutaneous (SC) every four weeks (Q4W)
Study NCT03691974 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) every four weeks (Q4W)
Study NCT03678402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUP™ sock
Description: The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
Study NCT03485833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEO and EIO test
Description: velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
Study NCT01030510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the order of drug administration
Description: In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
Study NCT01659320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg twice daily for 8 weeks
Study NCT03889561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drink Tap
Description: The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
Study NCT01770925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-CPAP
Description: The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed.
Study NCT01770925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: n-BiPAP
Description: The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water).
Study NCT01770925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
Study NCT03939507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEP score available to the treating physician
Description: the treating physician knew the AEP score results
Study NCT01745146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASMT
Description: 8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
Study NCT01745146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRE
Description: 8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
Study NCT01826747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crinone (progesterone 8%, vaginal application)
Study NCT03605680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 100 mg, BID, oral tablets
Study NCT03605680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral tablet.
Study NCT03605680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID, oral tablet.
Study NCT03605680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200 mg, BID, oral tablets
Study NCT04046679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Skin bleomycin infusion through tattoo machine
Study NCT04046679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bleomycin
Description: Skin bleomycin infusion through tattoo machine
Study NCT04046679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline solution infusion through tattoo machine
Study NCT04046679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution infusion through tattoo machine
Study NCT04536597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quince seed jelly group
Description: Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
Study NCT04536597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk group
Description: Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
Study NCT04536597 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
Study NCT03083340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
Study NCT04450485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty
Study NCT02106312 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: dose reduction of preoperative radiotherapy in MLS
Description: A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
Study NCT03697187 — intervention group
Intervention type: DRUG
Intervention: rhC1INH
Description: Recombinant human C1 inhibitor
Study NCT02073773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.
Study NCT02073773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.
Study NCT02073773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality based therapy
Description: The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Description: Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate control
Description: Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Description: Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linoleic acid control
Description: Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin solution
Description: Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
Study NCT03883880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin control
Description: Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
Study NCT03582670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
Study NCT03582670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Process Training
Description: Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
Study NCT03582670 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training